Skip to main content
SpringerLink
Log in

American Society of Clinical Oncology

Advancing the Science of Clinical Oncology; 13–17 May 2005; Orlando, Florida, USA

  • Meeting Report
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. Full coverage of the conference is available as a virtual meeting on the ASCO website at http://www.asco.org/ac/1,1003,_12-002803,00.asp.

  2. Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases in First-line.

  3. Oxaliplatin/fluorouracil/folinic acid (leucovorin).

  4. Multicenter International Study of Oxaliplatin/FU-LV in the Adjuvant Treatment of Colon Cancer.

  5. Randomized, Prospective Study Comparing Three Regimens of Eloxatin Plus Fluoropyrimidine and Bevacizumab for Evaluation of Safety and Tolerability in First-Line Treatment of Patients with Advanced Colorectal Cancer.

References

  1. American Cancer Society. Cancer facts and figures 2005 [online]. Available from http://www.cancer.org/docroot/STT/stt_0.asp [Accessed 2005 Jul 12]

  2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177–82

    Article  PubMed  CAS  Google Scholar 

  3. Piccart-Gebhart, MJ. HERA: a randomized three-arm multicentric comparison of one year and two years of Herceptin versus no Herceptin in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  4. Romond EH, Perez EA, Byrant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operative breast cancer: combined analysis of NSABPB31/ NCCTG-N9831 [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  5. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004

    Google Scholar 

  6. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial — E4599 [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  7. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumours (GISTs) expressing KIT [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  8. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/ leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  9. Escudier B, et al. Randomized phase III trial of Raf kinase and VEGFR inhibitor sorafebniv (BAY 43–9006) in patients with advanced renal cell carcinoma [abstract 4510]. J Clin Oncol 2005; 23 Suppl.: 1093

    Google Scholar 

  10. Ratain MJ, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma [abstract 4544]. J Clin Oncol 2005; 23 Suppl.: 388

    Google Scholar 

  11. Price D, Stein E, and Goluboff P, et al. Double-blind, placebo-controlled trial of toremifene for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  12. Kochhar R, Khurana V, Kochhar R, et al. Statins reduce breast cancer risk: a case control study in female veterans [abstract 514]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  13. DeMichele A, Troxel A, Weber A, et al. Effect of raloxifene on endometrial cancer risk in a population-based, case-control study [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  14. Thurlimann BJ, Keshaviah H, Mouridsen L, et al. BIG 1–98: Randomised doubleblind phase III study to evaluate letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  15. Goldstein L, O’Neill J, Sparano E, et al. E2197: phase III AT (doxorubicin/ docetaxel) vs. AC (doxorucicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  16. Miller KD, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first line therapy for locally recurrent or metastatic breast cancer [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  17. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid versus 5-FU/FA in stage III colon cancer patients (PETACC-3) [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  18. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract 3500]. J Clin Oncol 2005; 23 (16 Suppl.): 1092s

    Google Scholar 

  19. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract 3501]. J Clin Oncol 2005; 23 (16 Suppl.): 246s

    Google Scholar 

  20. Hochster H, Welles L, Hart L, et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic cancer: TREE 1 and 2 studies [abstract 3515]. J Clin Oncol 2005; 23 (16 Suppl.): 249s

    Google Scholar 

  21. Langer CJ, Socinski MA, Ross H, et al. Paclitaxel poliglumex/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapynative advanced non-small cell lung cancer: a phase III study [abstract]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  22. Saltz L. Adjuvant therapy of colon cancer: where are we now? [discussion]. 41st Annual Conference of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Ltd, Auckland, New Zealand

    Sue Pochon

Authors
  1. Sue Pochon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pochon, S. American Society of Clinical Oncology. Int J Pharm Med 19, 109–112 (2005). https://doi.org/10.2165/00124363-200519020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200519020-00007

Keywords

Search

Navigation